100,795 Shares in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Bought by Franklin Resources Inc.

Franklin Resources Inc. acquired a new position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 100,795 shares of the company’s stock, valued at approximately $201,000.

A number of other large investors have also recently made changes to their positions in TSHA. Bank of New York Mellon Corp bought a new position in shares of Taysha Gene Therapies in the 2nd quarter valued at about $1,018,000. Principal Financial Group Inc. purchased a new position in shares of Taysha Gene Therapies in the 2nd quarter worth approximately $48,000. Rhumbline Advisers bought a new position in shares of Taysha Gene Therapies during the 2nd quarter valued at approximately $413,000. The Manufacturers Life Insurance Company raised its holdings in Taysha Gene Therapies by 109.0% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 133,213 shares of the company’s stock valued at $298,000 after buying an additional 69,487 shares during the period. Finally, Scientech Research LLC bought a new stake in Taysha Gene Therapies in the second quarter worth $97,000. 77.70% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts have weighed in on the stock. Canaccord Genuity Group boosted their price objective on shares of Taysha Gene Therapies from $6.00 to $8.00 and gave the company a “buy” rating in a research report on Friday, November 15th. Cantor Fitzgerald reissued an “overweight” rating and issued a $7.00 price objective on shares of Taysha Gene Therapies in a research report on Tuesday, November 12th. Chardan Capital restated a “buy” rating and set a $7.00 target price on shares of Taysha Gene Therapies in a research report on Thursday, November 14th. JMP Securities reiterated a “market outperform” rating and issued a $5.00 price target on shares of Taysha Gene Therapies in a report on Tuesday, November 12th. Finally, Needham & Company LLC restated a “buy” rating and set a $6.00 price objective on shares of Taysha Gene Therapies in a report on Tuesday, November 12th. Eight research analysts have rated the stock with a buy rating, According to MarketBeat.com, Taysha Gene Therapies presently has an average rating of “Buy” and a consensus target price of $6.63.

Taysha Gene Therapies Stock Up 6.9 %

Shares of NASDAQ:TSHA opened at $1.85 on Friday. The business’s 50 day moving average is $2.10 and its 200 day moving average is $2.18. The stock has a market cap of $379.14 million, a P/E ratio of 2.94 and a beta of 0.79. Taysha Gene Therapies, Inc. has a 52-week low of $1.19 and a 52-week high of $4.32. The company has a quick ratio of 5.51, a current ratio of 5.51 and a debt-to-equity ratio of 0.48.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.